Biotech firm Absci dips on stock offering

** Absci Corp's  ABSI.O  shares down 2% at $4.82 premarket
after follow-on offering priced
    ** Artificial intelligence (AI) biologics firm late Tues
announced 16.7 mln shares at $4.50 for $75 mln raise with Morgan
Stanley and TD Cowen as joint bookrunners  
    ** Offering price represents 8.5% discount to stock's last
sale
    ** Absci said plans to use net proceeds to fund development
of its internal asset programs, invest in its Integrated Drug
Creation platform, including related AI and wet-lab technologies
    ** Co has 92,9 mln shares outstanding for $457 mln market
value, and 68.1 mln shares of public float, according to LSEG
data
    ** ABSI has been on a tear recently, having more than
tripled over the past three months. In early Dec, co inked a
cancer-fighting antibody deal with UK-based drugmaker
AstraZeneca  AZN.L 

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-646-279-6380))

Recent news on AbSci

See all news